Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma

被引:125
作者
Gill, PS
Tulpule, A
Espina, BM
Cabriales, S
Bresnahan, J
Ilaw, M
Louie, S
Gustafson, NF
Brown, MA
Orcutt, C
Winograd, B
Scadden, DT
机构
[1] Univ So Calif, Kenneth Norris Canc Hosp & Res Inst, Dept Med, Los Angeles, CA 90033 USA
[2] Univ So Calif, Kenneth Norris Canc Hosp & Res Inst, Dept Pharm, Los Angeles, CA 90033 USA
[3] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
[4] Harvard Univ, New England Deaconess Hosp, Dept Med, Boston, MA 02215 USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
D O I
10.1200/JCO.1999.17.6.1876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Liposomal anthracyclines are the present standard treatment for advanced AIDS-related Kaposi's sarcoma (KS). No effective therapies have been defined for use after treatment failure of these agents, A phase II trial was thus conducted with paclitaxel in patients with advanced KS ta assess safety and antitumor activity. Materials and Methods: A regimen of paclitaxel at a dose of 100 mg/m(2) was given every 2 weeks to patients with advanced AIDS-related KS. patients. were treated until complete remission, disease progression, or unacceptable toxicity occurred. Results: Fifty-six patients with advanced AIDS-related KS were accrued. Tumor-associated edema was present in 70% of patients and visceral involvement in 45%. Forty patients (71%) had received prior systemic therapy; 31 of these were resistant to an anthracycline., The median entry CD4(+) lymphocyte count was 20 cells/ mm(3) (range, 0 to 358). A median of 10 cycles (range, 1 ta 54+) of paclitaxel was administered. Fifty-nine percent of patients showed complete (n = 1) or partial response(n = 32) to paclitaxel. The median duration of response was 10.4 months (range, 2.8 to 26.7+ months) and the median survival was 15.4 months. The main side effects of therapy were grade 3 or 4 neutropenia in 61% of patients and mild-to-moderate alopecia in 87%. Conclusion: Paclitaxel at 100 mg/m(2) given every 2 weeks is active and well tolerated in the treatment of advanced and previously treated AIDS-related KS. The median duration of response is among the longest observed for any regimen or single agent reported far AIDS-related KS. Paclitaxel at this dosage and schedule is a treatment option for patients with advanced AIDS-related KS, including those who have experienced treatment failure of prior systemic therapy. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:1876 / 1883
页数:8
相关论文
共 28 条
[1]  
Blum L, 1997, AIDS, V11, P1653
[2]  
BOGNER JR, 1994, J ACQ IMMUN DEF SYND, V7, P463
[3]   PROGNOSTIC FACTORS AND STAGING CLASSIFICATION OF PATIENTS WITH EPIDEMIC KAPOSIS SARCOMA [J].
CHACHOUA, A ;
KRIGEL, R ;
LAFLEUR, F ;
OSTREICHER, R ;
SPEER, M ;
LAUBENSTEIN, L ;
WERNZ, J ;
RUBENSTEIN, P ;
ZANG, E ;
FRIEDMANKIEN, A .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (06) :774-780
[4]  
Gelmann E P, 1987, Am J Med, V82, P456, DOI 10.1016/0002-9343(87)90445-1
[5]  
GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V
[6]   Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma [J].
Gill, PS ;
Wernz, J ;
Scadden, DT ;
Cohen, P ;
Mukwaya, GM ;
vonRoenn, JH ;
Jacobs, M ;
Kempin, S ;
Silverberg, I ;
Gonzales, G ;
Rarick, MU ;
Myers, AM ;
Shepherd, F ;
Sawka, C ;
Pike, MC ;
Ross, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2353-2364
[7]   PHASE I/II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN [J].
GILL, PS ;
ESPINA, BM ;
MUGGIA, F ;
CABRIALES, S ;
TULPULE, A ;
ESPLIN, JA ;
LIEBMAN, HA ;
FORSSEN, E ;
ROSS, ME ;
LEVINE, AM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :996-1003
[8]  
Gill PS, 1994, AIDS UPDATES, V7, P1
[9]   SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].
GREEN, S ;
WEISS, GR .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253
[10]  
HOLMES FA, 1991, J NATL CANCER I, V83, P1979